Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax ...

The lithium companies will have to create a new royalty rate proposal, another delay for the commercial extraction of the ...

We’re now just days away from the ’24 elections, and what a race it’s been. Polls have been all over the place, and both ...

The Canadian healthcare-focused royalty company said Monday that the royalty interest in the worldwide net sales of all formulations of sebetralstat from KalVista Pharmaceuticals was acquired for an ...

Syndax has entered into a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo.

The lithium companies brought in an army of experts to make the case that their proposed royalty rate is on par with other ...

Another growth factor is Royalty’s customer attention. “We give them what they want and what they didn’t know they wanted,” Blatt says. That means communicating with customers and spending time with ...

The stock was up 11% to $11.73 on Monday. Shares have jumped 37% over the past 12 months. The pharmaceutical company said the proceeds of the royalty financing deal will be used t ...

On Monday, Royalty Pharma plc (RPRX) stock saw a modest uptick, ending the day at $27.2 which represents a slight increase of $0.10 or 0.37% from the prior close of $27.1. The stock opened at $27.52 ...

Provides Royalty Management with an equity interest and royalty stream from sales of patented products that serve the indoor farming and controlled agriculture spaces.Investment continues Company ...

Arm Holdings ( ARM -0.30%) has been a rising star in the semiconductor industry. Its technology is used in half of all chips ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 mil ...